报价延迟最少15分钟:2025/09/18 04:15 EDT
盘前时段
|
||||
|
-- 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
57.19
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.35/-2.23
|
|
企业价值
8.22B
|
| 资产负债 |
|
每股账面净值
-2.45
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
739.02M
|
|
每股收益
4.30
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/18 04:15 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD,test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
